Skip to main content

Table 2 a. EQ-5D mean (SD) domain scores and utility score for Adults (18 years and older) in Control group (N = 27) and Intervention group (N = 26; total N = 53)

From: Cost-effectiveness of a nurse-led telemonitoring intervention based on peak expiratory flow measurements in asthmatics: results of a randomised controlled trial

EuroQol

Baseline

Month 4

Month 8

Month 12

  
 

Control

Intervention

Control

Intervention

Control

Intervention

Control

Intervention

time 1

time*group 2

         

P

Mobility

1.37 (0.49)

1.15 (0.37)

1.32 (0.46)

1.00 (0.00)

1.35 (0.55)

1.15 (0.37)

1.30 (0.47)

1.54 (0.37)

.000

.1903

Self care

1.07 (0.27)

1.00 (0.00)

1.04 (0.19)

1.04 (0.20)

1.11 (0.32)

1.04 (0.20)

1.22 (0.42)

1.04 (0.20)

.000

.2134

Daily activities

1.48 (0.51)

1.35 (0.49)

1.54 (0.50)

1.31 (0.47)

1.54 (0.57)

1.42 (0.58)

1.56 (0.58)

1.46 (0.51)

.004

.6233

Pain/discomfort

1.67 (0.56)

1.31 (0.47)

1.54 (0.57)

1.23 (0.43)

1.56 (0.58)

1.35 (0.49)

1.63 (0.63)

1.42 (0.50)

.000

.8714

Anxiety/depression

1.11 (0.32)

1.19 (0.40)

1.22 (0.42)

1.15 (0.37)

1.19 (0.40)

1.27 (0.45)

1.19 (0.40)

1.15 (0.37)

.001

.5054

VAS

67.33 (17.20)

74.57 (12.78)

71.67 (17.63)

73.08 (14.29)

68.11 (19.06)

71.35 (18.45)

72.26 (18.43)

74.50 (15.87)

.081

.6384

Utility

0.78 (0.17)

0.89 (0.13)

0.80 (0.18)

0.91 (0.12)

0.78 (0.24)

0.86 (0.19)

0.79 (0.21)

0.90 (0.11)

.010

.5963

b. EQ-5D mean (SD) domain scores and utility score for Children (7 to 18 years) in Control group (N = 27) and Intervention group (N = 29); total N = 56

EuroQol

Baseline

Month 4

Month 8

Month 12

  
 

Control

Intervention

Control

Intervention

Control

Intervention

Control

Intervention

time 1

time*group 2

         

P

Mobility

1.00 (0.00)

1.00 (0.00)

1.00 (0.00)

1.00 (0.00)

1.00 (0.00)

1.00 (0.00)

1.00 (0.00)

1.04 (0.19)

-

.4284

Self care

1.00 (0.00)

1.00 (0.00)

1.00 (0.00)

1.00 (0.00)

1.00 (0.00)

1.00 (0.00)

1.00 (0.00)

1.00 (0.00)

-

-

Daily activities

1.15 (0.36)

1.21 (0.49)

1.07 (0.27)

1.09 (0.30)

1.04 (0.19)

1.14 (0.35)

1.11 (0.32)

1.14 (0.35)

.000

.6214

Pain/discomfort

1.04 (0.19)

1.18 (0.47)

1.04 (0.19)

1.01 (0.03)

1.04 (0.19)

1.04 (0.19)

1.07 (0.27)

1.07 (0.26)

.000

.8073

Anxiety/depression

1.11 (0.32)

1.10 (0.31)

1.04 (0.19)

1.00 (0.00)

1.07 (0.27)

1.04 (0.19)

1.15 (0.36)

1.00 (0.00)

.000

.0643

VAS

81.36 (11.70)

79.61 (13.67)

84.32 (10.72)

81.29 (12.02)

83.32 (13.11)

82.59 (11.39)

81.33 (14.69)

82.31 (12.49)

.000

.5214

Utility

0.96 (0.07)

0.92 (0.20)

0.98 (0.07)

0.99 (0.03)

0.98 (0.06)

0.98 (0.07)

0.97 (0.05)

0.98 (0.04)

.000

.5573

  1. P-values based on Repeated Measures ANCOVA corrected for baseline; performed separately for age group (adults/children).
  2. 1 p-value for overall follow-up in time.
  3. 2 p-value for follow-up difference in time between groups.
  4. 3 Greenhouse-Geisser.
  5. 4 Sphericity Assumed.
  6. - = analyses could not be performed due to minimal to zero variance